AstraZeneca announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs).

GlaxoSmithKline provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of Cervarix®, its vaccine to prevent cervical cancer.

The Novartis Institute for Tropical Diseases (NITD) and the Global Alliance for TB Drug Development (TB Alliance) announced a five-year research collaboration designed to yield new medicines for TB, including drug-resistant TB.

Roche announced that its ownership stake in Chugai will increase from 50.1% to 59.9% following the successful completion of the tender offer which started on 23 May. Chugai shareholders had the opportunity to tender their shares at a price of Yen 1,730 per share, which reflects a premium of 11.7% over Chugai’s share price of Yen 1,549 at the close of trading on 21 May 2008.

A house is the one place where a family should feel safe and secure, yet it is here that teens are prone to get prescription drugs to misuse and abuse. To help prevent teen prescription drug misuse and abuse, the Partnership for a Drug-Free America(R) and Abbott today launched "Not In My House", a national education initiative that provides parents with useful information and tips to help them limit teen access to medicines.

Bayer and Barr Laboratories Inc. today signed supply and licensing agreements for Yasmin® and YAZ® for the United States. Bayer will supply U.S. generics manufacturer Barr, starting July 1, 2008 at the latest, with a generic version of its oral contraceptive Yasmin, which Barr will market solely in the United States.

GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme.